Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

64.40 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
 
Via Benzinga
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
Earnings Scheduled For April 30, 2025
 
Via Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
 
Via Benzinga
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
Analyst Expectations For Ionis Pharmaceuticals's Future
 
Via Benzinga
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts
 
Via Benzinga
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to host 2025 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts
 
Via Benzinga
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products. 
Via Benzinga
Ionis reports first quarter 2025 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
 
Via Benzinga
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales. 
Via Benzinga
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS